Morning Overview on MSN
The FDA cleared a three-drug maintenance combination for HER2-positive breast cancer built around tucatinib
Tucatinib, trastuzumab and pertuzumab became an approved maintenance regimen on Oct. 7, 2026, when the Food and Drug ...
A new case report in the Annals of Hematology describes a woman whose rare primary thyroid diffuse large B-cell lymphoma ...
Experts said the lawsuits represent an unprecedented attempt to use public nuisance law, traditionally applied in ...
NEW YORK – New York Attorney General Letitia James today joined a bipartisan coalition of 47 other attorneys general in securing $1 million from Ascend ...
Pfizer bagged a coveted first-line maintenance approval for Tukysa. In combination with HER2 antibody drugs, the treatment ...
United States President Donald Trump has been traveling all across the country over the past several weeks, speaking at rallies and political events ahead of next month’s midterm elections. On ...
Christa Pike is the first known prisoner to survive a lethal injection. Christa Pike, a Tennessee death row inmate who ...
Tukysa adds a chemotherapy-free maintenance option for HER2-positive metastatic breast cancer; liver toxicity monitoring ...
Christa Pike has regained consciousness and is speaking a week after receiving two doses of execution drugs in Tennessee ...
Tucatinib FDA approval expands TUKYSA into first-line HER2+ metastatic breast cancer maintenance after HER2CLIMB-05 improved ...
The HER2CLIMB-05 trial is a randomized, double blind, placebo-controlled, pivotal Phase 3 study evaluating the efficacy and safety of TUKYSA compared to placebo, both in combination with trastuzumab ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results